QuoTrend
DashboardScreenCompareStrategiesPortfolioSectorsHeatmapsInsiderFuturesForexCryptoCalendarNews
DashboardScreenCompareStrategiesPortfolioSectorsHeatmapsInsiderFuturesForexCryptoCalendarNewsMore
⌘K
Help
QuoTrend
PAGEHome
HomePricingContactHelpTermsPrivacy
Quotes delayed 15 minutes for NASDAQ, NYSE and AMEX.
© 2026 QuoTrend
Screen

WST

QT67West Pharmaceutical Services, Inc.
NYSE·Healthcare·Medical - Instruments & Supplies·USA
Latest market price
327.95
+4.36+1.35%
OverviewShort InterestFilings
WSTQT67West Pharmaceutical Services, Inc.·NYSE
OverviewShort InterestFilings
327.95+1.35%
TA
Loading chart...
Screen all →
BDX+1.67%$143.98ALC+0.84%$64.68MDLN-1.32%$35.94COO+1.32%$65.91BAX+2.58%$19.89ATR+0.28%$120.32RGEN-1.15%$132.02AVTR+1.27%$9.58
Snapshot
Index-P/E42.93EPS (ttm)7.49
Insider Own1.02%
Shs Outstand70.65M
Perf Week-0.72%
Market Cap22.86BForward P/E34.24EPS next Y9.58Insider Trans0.03%Shs Float-Perf Month7.90%
Enterprise Value22.66BPEG2.51EPS next Q2.08Inst Own-Short Float-Perf Quarter36.46%
Income532.66MP/S7.10EPS this Y14.98%Inst Trans-Short Ratio-Perf Half Y23.09%
Sales3.22BP/B7.79EPS next Y11.23%ROA13.21%Short Interest-Perf YTD19.19%
Book/sh42.32P/C32.57EPS next 5Y9.62%ROE17.87%52W High336.81 -2.63%Perf Year50.39%
Cash/sh7.37P/FCF49.91EPS past 3/5Y-ROIC15.24%52W Low206.80 58.58%Perf 3Y-
Dividend Est.0.87 (0.27%)EV/EBITDA28.36Sales past 3/5Y2.13% 7.44%Gross Margin36.24%Volatility1.30% 1.81%Perf 5Y-
Dividend TTM0.87 (0.27%)EV/Sales7.04EPS Y/Y TTM19.13%Oper. Margin20.67%ATR (14)8.22Perf 10Y-
Dividend Ex-DateApr 29, 2026Quick Ratio2.04Sales Y/Y TTM11.30%Profit Margin16.85%RSI (14)59.38Recom2.20
Dividend Gr. 3/5Y5.20% 5.51%Current Ratio2.71EPS Q/Q46.90%SMA201.85%Beta0.75Target Price330.83
Payout11.39%Debt/Eq0.11Sales Q/Q21.06%SMA507.54%Rel Volume1.74Prev Close323.59
Employees10,600LT Debt/Eq0.12EarningsJul 23SMA20020.73%Avg Volume847.78KPrice327.95
IPO DateMar 17, 1980Option/ShortYes / YesEPS/Sales Surpr.26.79% 8.33%Net Debt/EBITDA-0.26Volume1,479,259Change1.35%
Analyst Ratings
DateActionAnalystRatingTarget
Jun-09-26UpgradeBarclaysEqual Weight → Overweight$310 → $400
Apr-27-26ReiteratedMorgan Stanley$285 → $315
Apr-27-26ReiteratedBarclaysEqual Weight$265 → $310
Feb-13-26ReiteratedUBSBuy$355 → $340
Feb-13-26ReiteratedDeutsche BankHold$310 → $315
Feb-13-26ReiteratedBarclaysEqual Weight$325 → $265
Feb-10-26ReiteratedJefferiesBuy$365 → $295
Feb-03-26ReiteratedEvercore ISI$390 → $320
Dec-01-25InitiatedMorgan StanleyEqual Weight$285
Oct-27-25ReiteratedBarclaysEqual Weight$275 → $325
Latest News
Jun-17-26
Jun-17-2603:16PM
Reasons to Retain QuidelOrtho Stock in Your Portfolio for NowYahoo
02:14PM
LivaNova Reports Improved OSA Outcomes With PolySync ProgrammingYahoo
Jun-16-26
Jun-16-2606:14PM
Reasons to Retain Baxter International Stock in Your Portfolio for NowYahoo
04:41PM
InspireMD Posts Positive CGUARDIANS II Data for CGuard Prime TCARYahoo
01:55PM
DXCM Receives FDA Clearance for Stelo OTC CGM System for ChildrenYahoo
01:54PM
Here's Why You Should Retain BDX Stock in Your Portfolio NowYahoo
01:09AM
How Investors May Respond To West Pharmaceutical Services (WST) Upgraded 2026 Outlook And Biologics MomentumYahoo
Jun-15-26
Jun-15-2603:16PM
QIAGEN Expands QIAcuity Gene Expression Portfolio to Drive dPCR UseYahoo
02:50PM
GEHC Expands Carilion Tie to Enhance Patient Care Across VirginiaYahoo
06:55AM
Is West Pharmaceutical Stock Outperforming the S&P 500?Yahoo
Jun-12-26
Jun-12-2605:16PM
Here's Why You Should Hold Stryker Stock in Your Portfolio for NowYahoo
03:09PM
Veeva Expands Safety Suite Footprint With UCB Pharmacovigilance DealYahoo
03:06PM
Reasons to Hold HealthEquity Stock in Your Portfolio for NowYahoo
01:15PM
Organon Wins FDA Nod to Expand TOFIDENCE Use in Severe CRS & COVID-19Yahoo
Jun-11-26
Jun-11-2605:06PM
Senseonics Expands Eversense 365 Ecosystem With Welldoc PartnershipYahoo
Company
Ownership

Per-holder 13F data hasn't been ingested for this ticker yet.

Financial Statements
DataTimeframe
Line Item (USD, M)
TTM
—
FY 2025
12/31/2025
FY 2024
12/31/2024
FY 2023
12/31/2023
FY 2022
12/31/2022
FY 2021
12/31/2021
FY 2020
12/31/2020
FY 2019
12/31/2019
FY 2018
12/31/2018
Total Revenue3,2203,0742,893
Upgrade your experience to unlock full historical data
Cost of Goods Sold Incl. D&A2,0541,9701,891
Gross Profit1,1671,1031,002
Selling, General and Administrative Excl. Other406393339
Research and Development747469
Other Operating Expense21190
Operating Income666617595
Interest Expense013
Unusual Expense
———
Non-Operating Income (Expense)-2186
Net Income Before Taxes681615600
Income Taxes142122108
Consolidated Net Income543494493
Net Income From Continuing Operations539494493
Net Income543494493
EPS (Recurring)7.526.836.75
EPS (Basic, Before Extraordinaries)7.526.836.75
EPS (Diluted)7.496.806.69
EBITDA845724744
Other After Tax Adjustments
———
Stock Option Compensation Expense
———
Price To Earnings Ratio43.7940.46—
Price To Sales Ratio7.336.44—
Gross Margin36.2435.8834.64
Operating Margin20.6820.0720.57
Net Margin16.8616.0717.04
Shares Outstanding727273
Market Capitalization23,61219,810—
Operating Lease Expense
———
Insider Trading Volume
$373.13$339.24$305.35$271.46$237.57● Close Price0.00M0.28M0.56M0.85M1.13MUSD Trades VolumeJunJulAugSepOctNovDec2026FebMarAprMayJun
Insider Trading
InsiderRelationshipDateTransactionCost#SharesValue ($)#Shares TotalSEC Form 4
Campbell Shane AldenSVP, Proprietary SegmentMay 12 '26Option Exercise0.001,54001,417May 14 12:00 AM
Favorite Annette FSr. VP & Chief HR OfficerApr 27 '26Option Exercise83.475,634470,27019,645Apr 29 12:00 AM
Winters ChadVP, Chief Accounting OfficerApr 27 '26Sale300.67896269,3991,523Apr 29 12:00 AM
Winters ChadVP, Chief Accounting OfficerApr 27 '26Option Exercise173.221,792310,4102,419Apr 29 12:00 AM
Favorite Annette FSr. VP & Chief HR OfficerApr 27 '26Sale305.202,817859,75316,828Apr 29 12:00 AM
Poussot Rodolphe JeanSVP, Strategy & Corporate DevFeb 20 '26Option Exercise0.007660691Feb 23 12:00 AM
Witherspoon CharlesVP & TreasurerFeb 20 '26Option Exercise0.0012001,430Feb 23 12:00 AM
Winters ChadVP, Chief Accounting OfficerFeb 20 '26Option Exercise0.0017801,553Feb 23 12:00 AM
Poussot Rodolphe JeanSVP, Strategy & Corporate DevFeb 18 '26Option Exercise0.001640335Feb 19 12:00 AM
Green Eric MarkPresident, CEO and Board ChairFeb 18 '26Option Exercise0.002,6380175,734Feb 19 12:00 AM
Favorite Annette FSr. VP & Chief HR OfficerFeb 18 '26Option Exercise0.00270017,410Feb 19 12:00 AM
McMahon Robert W.SVP & Chief Financial OfficerFeb 11 '26Option Exercise0.008,46208,462Feb 12 12:00 AM
Birkett BernardSr VP, Chief Financial OfficerFeb 18 '25Option Exercise211.00904190,8137,669Feb 20 12:00 AM
Reiss-Clark CindyChief Commercial OfficerFeb 18 '25Option Exercise211.0024651,9405,131Feb 20 12:00 AM
MacKay Kimberly BanksSVP, GC & Corporate SecretaryFeb 18 '25Option Exercise211.0024651,9401,605Feb 20 12:00 AM
open in yahoo·open in reuters·open in marketwatch·open in google·open in EDGAR